Missed treatment opportunities for schistosomiasis mansoni, in an active programme for the treatment of urinary schistosomiasis in Plateau and Nasarawa states, Nigeria.
Both Schistosoma haematobium and S. mansoni are endemic in Nigeria. Since 1999 the ministries of health of Plateau and Nasarawa states, assisted by The Carter Center, have provided mass drug administrations with praziquantel to villages where >20% of the school-aged children tested with urine dipsticks have been found to have haematuria (presumed to be caused by S. haematobium). The current extent of S. mansoni in Nigeria remains relatively unknown because the tests needed to detect human infection with this parasite are difficult to perform in many endemic areas. In a cross-sectional survey involving 924 children, the prevalence of S. mansoni was determined in 30 villages (in four local government areas) that had been excluded from mass praziquantel administrations because the prevalence of haematuria in their school-aged children had been found to be <20%. Seventeen (57%) of the surveyed villages had sufficient S. mansoni (i.e. prevalences of at least 10%) to warrant treatment. The results indicated that, if both S. haematobium and S. mansoni are taken into account, 81% of the villages in the four local government areas studied require treatment, compared with 50% if only S. haematobium is considered. At the moment, the costs of the village-by-village diagnosis of S. haematobium and S. mansoni would be greater than those of the presumptive treatment of the school-aged children in all villages. Until improved and cheaper rapid diagnostic methods for S. mansoni become available, the cheapest approach to the overall problem of schistosomiasis in this part of Nigeria would therefore be wide-spread mass drug distributions, without screening for at-risk populations.
Gutman
J
J
Department of Pediatric Infectious Disease, Emory University School of Medicine, Atlanta, GA 30322, USA. gutmanjr@gmail.com
Fagbemi
A
A
Alphonsus
K
K
Eigege
A
A
Miri
E S
ES
Richards
F O
FO
D000293:Adolescent; D000818:Animals; D000871:Anthelmintics / Q000008:administration & dosage; D002648:Child; D003430:Cross-Sectional Studies; D019353:Endemic Diseases; D005243:Feces / Q000469:parasitology*; D005260:Female; D006417:Hematuria / Q000469:parasitology*; D006801:Humans; D008297:Male; D020380:Needs Assessment; D009549:Nigeria / Q000453:epidemiology; D010270:Parasite Egg Count; D011223:Praziquantel / Q000008:administration & dosage; D012423:Rural Health; D012553:Schistosomiasis haematobia / Q000188:drug therapy* / Q000453:epidemiology; D012555:Schistosomiasis mansoni / Q000188:drug therapy* / Q000453:epidemiology
D000871:Anthelmintics; D011223:Praziquantel